- Home
- HYPR vs OTLK Comparison
HYPR vs OTLK Comparison
Compare HYPR & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HYPR
- OTLK
- Stock Information
- Founded
- HYPR 2014
- OTLK 2010
- Country
- HYPR United States
- OTLK United States
- Employees
- HYPR N/A
- OTLK N/A
- Industry
- HYPR Medical Specialities
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HYPR Health Care
- OTLK Health Care
- Exchange
- HYPR Nasdaq
- OTLK Nasdaq
- Market Cap
- HYPR 55.9M
- OTLK 48.3M
- IPO Year
- HYPR N/A
- OTLK 2016
- Fundamental
- Price
- HYPR $1.20
- OTLK $0.94
- Analyst Decision
- HYPR Strong Buy
- OTLK Buy
- Analyst Count
- HYPR 3
- OTLK 5
- Target Price
- HYPR $1.28
- OTLK $8.50
- AVG Volume (30 Days)
- HYPR 363.4K
- OTLK 7.8M
- Earning Date
- HYPR 08-13-2025
- OTLK 08-14-2025
- Dividend Yield
- HYPR N/A
- OTLK N/A
- EPS Growth
- HYPR N/A
- OTLK N/A
- EPS
- HYPR N/A
- OTLK N/A
- Revenue
- HYPR $10,797,000.00
- OTLK $1,505,322.00
- Revenue This Year
- HYPR $12.92
- OTLK N/A
- Revenue Next Year
- HYPR $32.10
- OTLK $484.88
- P/E Ratio
- HYPR N/A
- OTLK N/A
- Revenue Growth
- HYPR N/A
- OTLK N/A
- 52 Week Low
- HYPR $0.53
- OTLK $0.79
- 52 Week High
- HYPR $1.90
- OTLK $8.32
- Technical
- Relative Strength Index (RSI)
- HYPR 51.58
- OTLK 32.01
- Support Level
- HYPR $1.06
- OTLK $0.82
- Resistance Level
- HYPR $1.28
- OTLK $0.98
- Average True Range (ATR)
- HYPR 0.07
- OTLK 0.29
- MACD
- HYPR -0.03
- OTLK -0.17
- Stochastic Oscillator
- HYPR 50.00
- OTLK 5.78
About HYPR Hyperfine Inc.
Hyperfine Inc is a medical device company that created Swoop. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength than conventional MRI scanners. The company derives its revenue from sale of sales of MRI devices and service sales which consist of sales from subscriptions of bundled devices, maintenance, and software.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.